126 related articles for article (PubMed ID: 32984850)
1. Renin-Angiotensin-Aldosterone System Modulates Blood Pressure Response During Vascular Endothelial Growth Factor Receptor Inhibition.
Bottinor WJ; Shuey MM; Manouchehri A; Farber-Eger EH; Xu M; Nair D; Salem JE; Wang TJ; Brittain EL
JACC CardioOncol; 2019 Sep; 1(1):14-23. PubMed ID: 32984850
[TBL] [Abstract][Full Text] [Related]
2. Treatment and Implications of Vascular Endothelial Growth Factor Inhibitor-Induced Blood Pressure Rise: A Clinical Cohort Study.
van Dorst DCH; Kabadayi S; Oomen-de Hoop E; Danser AHJ; Mathijssen RHJ; Versmissen J
J Am Heart Assoc; 2023 Jan; 12(1):e028050. PubMed ID: 36583425
[TBL] [Abstract][Full Text] [Related]
3. RAAS inhibitors directly reduce diabetes-induced renal fibrosis via growth factor inhibition.
Koszegi S; Molnar A; Lenart L; Hodrea J; Balogh DB; Lakat T; Szkibinszkij E; Hosszu A; Sparding N; Genovese F; Wagner L; Vannay A; Szabo AJ; Fekete A
J Physiol; 2019 Jan; 597(1):193-209. PubMed ID: 30324679
[TBL] [Abstract][Full Text] [Related]
4. Renoprotective RAAS inhibition does not affect the association between worse renal function and higher plasma aldosterone levels.
Gant CM; Laverman GD; Vogt L; Slagman MCJ; Heerspink HJL; Waanders F; Hemmelder MH; Navis G;
BMC Nephrol; 2017 Dec; 18(1):370. PubMed ID: 29262813
[TBL] [Abstract][Full Text] [Related]
5. DOPPS data suggest a possible survival benefit of renin angiotensin-aldosterone system inhibitors and other antihypertensive medications for hemodialysis patients.
Karaboyas A; Xu H; Morgenstern H; Locatelli F; Jadoul M; Nitta K; Dasgupta I; Tentori F; Port FK; Robinson BM
Kidney Int; 2018 Sep; 94(3):589-598. PubMed ID: 29908836
[TBL] [Abstract][Full Text] [Related]
6. Cochrane in context: pharmacological interventions for hypertension in children.
Chaturvedi S; Lipszyc DH; Licht C; Craig JC; Parekh RS
Evid Based Child Health; 2014 Sep; 9(3):581-3. PubMed ID: 25236306
[TBL] [Abstract][Full Text] [Related]
7. Management of renin-angiotensin-aldosterone inhibitors and other antihypertensives and their clinical effects on pre-anesthesia blood pressure.
Balcı E; Demir ZA; Bahçecitapar M
Anesth Pain Med (Seoul); 2022 Jan; 17(1):112-119. PubMed ID: 34991190
[TBL] [Abstract][Full Text] [Related]
8. Does SGLT2 inhibition with dapagliflozin overcome individual therapy resistance to RAAS inhibition?
Petrykiv S; Laverman GD; de Zeeuw D; Heerspink HJL
Diabetes Obes Metab; 2018 Jan; 20(1):224-227. PubMed ID: 28685934
[TBL] [Abstract][Full Text] [Related]
9. Role of Renin-Angiotensin-Aldosterone System in Metabolic Syndrome and Obesity-related Hypertension.
Kamide K
Curr Hypertens Rev; 2014 Aug; ():. PubMed ID: 25115697
[TBL] [Abstract][Full Text] [Related]
10. Hyperkalemia and renin-angiotensin aldosterone system inhibitor therapy in chronic kidney disease: A general practice-based, observational study.
Jun M; Jardine MJ; Perkovic V; Pilard Q; Billot L; Rodgers A; Rogers K; Gallagher M
PLoS One; 2019; 14(3):e0213192. PubMed ID: 30845156
[TBL] [Abstract][Full Text] [Related]
11. Retrospective comparison of triple-sequence therapies in metastatic renal cell carcinoma.
Busch J; Seidel C; Erber B; Issever AS; Hinz S; Kempkensteffen C; Magheli A; Miller K; Grünwald V; Weikert S
Eur Urol; 2013 Jul; 64(1):62-70. PubMed ID: 22999519
[TBL] [Abstract][Full Text] [Related]
12. Dietary sodium restriction prevents vascular endothelial growth factor inhibitor-induced hypertension.
van Doorn L; Visser WJ; van Dorst DCH; Mirabito Colafella KM; Koolen SLW; de Mik AVE; Garrelds IM; Bovée DM; de Hoop EO; Bins S; Eskens FALM; Hoorn EJ; Jan Danser AH; Mathijssen RHJ; Versmissen J
Br J Cancer; 2023 Jan; 128(2):354-362. PubMed ID: 36357702
[TBL] [Abstract][Full Text] [Related]
13. Microparticles from vascular endothelial growth factor pathway inhibitor-treated cancer patients mediate endothelial cell injury.
Neves KB; Rios FJ; Jones R; Evans TRJ; Montezano AC; Touyz RM
Cardiovasc Res; 2019 Apr; 115(5):978-988. PubMed ID: 30753341
[TBL] [Abstract][Full Text] [Related]
14. Effects of hyperkalaemia and non-adherence to renin-angiotensin-aldosterone system inhibitor therapy in patients with heart failure in Italy: a propensity-matched study.
Volterrani M; Perrone V; Sangiorgi D; Giacomini E; Iellamo F; Degli Esposti L;
Eur J Heart Fail; 2020 Nov; 22(11):2049-2055. PubMed ID: 33459467
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological interventions for hypertension in children.
Chaturvedi S; Lipszyc DH; Licht C; Craig JC; Parekh R
Evid Based Child Health; 2014 Sep; 9(3):498-580. PubMed ID: 25236305
[TBL] [Abstract][Full Text] [Related]
16. Increased bowel toxicity in patients treated with a vascular endothelial growth factor inhibitor (VEGFI) after stereotactic body radiation therapy (SBRT).
Barney BM; Markovic SN; Laack NN; Miller RC; Sarkaria JN; Macdonald OK; Bauer HJ; Olivier KR
Int J Radiat Oncol Biol Phys; 2013 Sep; 87(1):73-80. PubMed ID: 23920388
[TBL] [Abstract][Full Text] [Related]
17. Impact of Angiotensin Blockade on Development of Chronic Lung Allograft Dysfunction.
January SE; Hubbard J; Fester KA; Dubrawka CA; Vazquez Guillamet R; Kulkarni HS; Hachem RR
J Pharm Pract; 2023 Nov; ():8971900231213699. PubMed ID: 37923307
[No Abstract] [Full Text] [Related]
18. Real-World Associations of Renin-Angiotensin-Aldosterone System Inhibitor Dose, Hyperkalemia, and Adverse Clinical Outcomes in a Cohort of Patients With New-Onset Chronic Kidney Disease or Heart Failure in the United Kingdom.
Linde C; Bakhai A; Furuland H; Evans M; McEwan P; Ayoubkhani D; Qin L
J Am Heart Assoc; 2019 Nov; 8(22):e012655. PubMed ID: 31711387
[TBL] [Abstract][Full Text] [Related]
19. Hypertension due to antiangiogenic cancer therapy with vascular endothelial growth factor inhibitors: understanding and managing a new syndrome.
Small HY; Montezano AC; Rios FJ; Savoia C; Touyz RM
Can J Cardiol; 2014 May; 30(5):534-43. PubMed ID: 24786444
[TBL] [Abstract][Full Text] [Related]
20. Aldosterone breakthrough during aliskiren, valsartan, and combination (aliskiren + valsartan) therapy.
Bomback AS; Rekhtman Y; Klemmer PJ; Canetta PA; Radhakrishnan J; Appel GB
J Am Soc Hypertens; 2012; 6(5):338-45. PubMed ID: 22995802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
